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Background: Data on both known and unknown drug use in the electronic dance music (EDM) 
scene is important to inform prevention and harm reduction. While surveys are the most 
common method of querying drug use, additional biological data can help validate use and 
detect unknown/unintentional use of drugs such as new psychoactive substances (NPS). We 
sought to determine the extent of both known and unknown use of various substances in this 
high-risk scene.   
Methods: We hair-tested 90 self-reported past-year ecstasy/MDMA/Molly users attending 
EDM parties in New York City during the summer of 2016 using UHPLC-MS/MS. Results were 
compared to self-reported past-year use.  
Results: Three quarters (74.4%) tested positive for MDMA, a third (33.3%) tested positive for an 
NPS, and 27.8% tested positive specifically for one or more synthetic cathinones (e.g., butylone, 
ethylone, pentylone, methylone, alpha-PVP). Half (51.1%) of participants tested positive for a 
drug not self-reported, with most testing positive for synthetic cathinones (72.0%), 
methamphetamine (69.0%), other NPS stimulants (e.g., 4-FA, 5/6-APB; 66.7%), or new 
dissociatives (e.g., methoxetamine, diphenidine; 60.0%). Attending parties every other week or 
more often, reporting higher-frequency ecstasy pill use, having tested one’s ecstasy, and having 
found out one’s ecstasy was adulterated, were risk factors for testing positive for synthetic 
cathinones and NPS in general. 
Conclusion: Hair testing appears to be a valuable addition to drug epidemiology studies. Many 
EDM party attendees—even those who test their ecstasy—are unknowingly using NPS and/or 
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other drugs. Prevention information and harm reduction may help reduce 
unknown/unintentional use.  























 Electronic dance music (EDM) parties are high-risk scenes for both known and unknown 
use of a variety of psychoactive substances. Recent studies indicate that illicit drug use is highly 
prevalent amongst nightclub and festival attendees (Hughes, Moxham-Hall, Ritter, 
Weatherburn, & MacCoun, 2017; Miller, Byrnes, Branner, Voas, & Johnson, 2013; Miller et al., 
2015; Nordfjaern, Bretteville-Jensen, Edland-Gryt, & Gripenberg, 2016; Palamar, Barratt, Ferris, 
& Winstock, 2016; Palamar, Griffin-Tomas, & Ompad, 2015; Palamar, Salomone, Vincenti, & 
Cleland, 2016). A recent national survey of Australian dance festival-attending adults found that 
78.1% of recent users reported using an illicit drug at their last-attended festival, and of users, 
85.1% reported use of ecstasy (Hughes et al., 2017). A recent study of EDM party attendees in 
New York City (NYC) estimated lifetime use of ecstasy/MDMA or “Molly” amongst young adult 
(age 18-25) attendees to be 42.8% (95% CI: 32.8, 52.7) (Palamar, Acosta, Ompad, & Cleland, 
2016). “Molly” is a common street name for powder or crystalline MDMA in the US; thus, since 
ecstasy and Molly are both street names for MDMA, some epidemiology surveys in the US now 
use these terms interchangeably or in combination (Palamar, 2017).  
 Dance festivals have become common in the US in recent years, and drug use amongst 
individuals in these scenes has been associated with severe adverse outcomes including death 
(Centers for Disease Control and Prevention, 2010; Friedman et al., 2017; Ridpath et al., 2014). 
For example, an investigation of 22 individuals poisoned at a large dance festival in NYC found 
that 65% (11 of 17) of individuals toxicology-tested after poisoning at a large dance festival 
tested positive for methylone (a synthetic cathinone) (Ridpath et al., 2014). However, it is 
unknown how many of these individuals were aware they were using methylone or if they 
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believed they were using MDMA. While use of more traditional drugs such as ecstasy in these 
environments is most common, hundreds of new psychoactive substances (NPS) such as 
methylone have emerged in recent years (European Monitoring Centre for Drugs and Drug 
Addiction, 2015; U.S. Drug Enforcement Administration, 2016) and many have been detected as 
adulterants in or replacements for traditional drugs such as ecstasy (Brunt et al., 2016; 
Caudevilla-Gálligo, Ventura, Indave Ruiz, & Fornís, 2013; Palamar et al., 2016a; Vidal Gine et al., 
2016). Biological confirmation of self-reported use is informative as it helps validate prevalence, 
but research on unintentional or unknown use of drugs—particularly NPS—is important to 
further guide continued prevention, education, and harm reduction efforts within these high-
risk scenes.  
 Researchers at European organisations such as Energy Control in Spain (Caudevilla-
Gálligo et al., 2013; Gine, Espinosa, & Vilamala, 2014), the Drug Information Monitoring System 
(DIMS) in the Netherlands (Brunt & Niesink, 2011), and international collaborative organisations 
such as the Trans European Drug Information (TEDI) project (Brunt et al., 2016) have been 
testing contents of traditional drugs such as ecstasy and have been detecting NPS such as 
synthetic cathinones in samples. NPS such as synthetic cathinones—alone or in combination 
with ecstasy or one another—especially if taken unknowingly, can potentially lead to a higher 
likelihood of adverse effects than solely MDMA (Brunt, Koeter, Niesink, & van den Brink, 2012). 
While these studies provide great insight into drug adulteration in Europe, very few formal 
drug-testing studies have been conducted in the US and these studies were conducted decades 
ago (e.g., Baggott et al., 2000; Renfroe, 1986). Moreover, while test results of drug product 
(e.g., pill/powder testing) are informative, research is also needed to help determine the 
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characteristics of individuals who have already (often unknowingly) used specific NPS—often 
under the assumption it is ecstasy or “Molly”.  
 Hair testing for NPS is an important new addition to biological testing. While blood, 
urine, and saliva are often adequate for assessing current intoxication or very recent use (use 
within the past few days) (Jufer, Walsh, Cone, & Sampson-Cone, 2006; Smith-Kielland, 
Skuterud, & Mørland, 1999; Vindenes et al., 2011; Wille et al., 2009), many drugs—including 
NPS—can be detected in hair months after use. For example, synthetic cathinones can be 
detected in hair samples 24 months after use (depending on length of hair) (Kintz, Salomone, & 
Vincenti, 2015; Lendoiro et al., 2017; Rust, Baumgartner, Dally, & Kraemer, 2012; Salomone, 
Palamar, Gerace, Di Corcia, & Vincenti, 2017; Vincenti, Salomone, Gerace, & Pirro, 2013). Most 
standard drug tests only test for select traditional drugs and not NPS; however, hair testing 
allows us to test for a wider array of substances and for a more extensive period after use. In 
2015, we piloted our hair-testing methodology as an addition to a drug use epidemiology 
survey of individuals in the EDM scene and published data derived from 48 ecstasy users 
(Palamar, Salomone, et al., 2016). However, results were limited, in part, because only lifetime 
drug use was queried. In this paper, we expand upon this original study and report on and 
compare self-reported past-year drug use and biological hair test results of 90 individuals in the 
EDM scene in NYC who reported past-year ecstasy use. Specifically, our aims of this study were 
to 1) determine prevalence of testing positive for specific drugs and drug classes, 2) determine 
the extent of discordant reporting (defined as reporting no use of a drug, but testing positive 
for that drug), and 3) delineate characteristics of testing positive or providing a discordant 
report for select drug classes. While we expected most individuals to test positive for MDMA, 
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we hypothesized that a large portion of individuals would test positive for drugs not reportedly 
used.   
 
Methods 
Participants and Procedure  
 1,087 individuals entering EDM parties in New York City were surveyed from May 
through September, 2016. Parties were randomly selected using time-space sampling 
(MacKellar et al., 2007; Palamar, Acosta, Sherman, Ompad, & Cleland, 2016). Individuals were 
eligible if they 1) were about to attend the selected party and 2) identified as age 18-40. 
Individuals were approached and asked if they were attending the randomly selected party. 
Those determined eligible were asked if they would take a survey about drug use. After 
providing informed consent, participants completed the survey on a tablet. Participants who 
completed the survey were compensated $10. Upon completion, a subset of participants was 
asked if they were willing to provide a hair sample to be tested for “new drugs such as ‘bath 
salts’”. If the participant agreed, the recruiter cut a small lock of hair (~100 hairs) from the 
participant—as close to his or her scalp as possible using a clean scissor. In some cases, male 
participants volunteered to clip or buzz body hair from the arm, chest, or leg with an electronic 
razor. Hair was folded in a piece of tin foil and stored in an envelope labelled with the 
participant’s study ID number which was linked to the participant’s survey responses. We 
collected 178 hair samples from a subset of those surveyed. Due to limited funding and 
extreme environmental conditions not conducive to hair testing (e.g., windy/rainy days) on 
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some recruitment days, we only obtained hair samples from a convenience sample of those 
surveyed.  
Measures   
Participants were asked their age, sex, race/ethnicity, and educational attainment. Age, 
race/ethnicity, and educational attainment were dichotomised into variables indicating 
whether they identified as age 25-40 (vs. age 18-24 [“young adults”]), white (vs. non-white), 
and having earned a college degree or higher (vs. less than a college degree), respectively. 
Participants were also asked how often they attended rave/nightclub/festival/dance parties 
with answer options: never, a few times a year, every couple of months, every month, every 
other week, and every week or more often (Palamar, Barratt, et al., 2016). We recoded 
attendance into a dichotomous variable (via median-split) indicating whether they attended at 
least every other week. Answers were recoded into attend less than once every other week vs. 
attend at least every other week.  
The survey asked participants about “known” lifetime and past-year use of a variety of 
traditional drugs and NPS. Drugs and drug classes queried included “ecstasy/MDMA/Molly”, 
other MDx drugs (e.g., MDA, MDEA), methamphetamine, amphetamine (nonmedical use), 
ketamine, PCP, and drugs commonly defined as NPS such as “bath salts” (synthetic cathinones), 
other NPS stimulants (e.g., 4-FA, 5/6-APB), dissociative NPS (e.g., methoxetamine [MXE]), 2C-B, 
and PMMA. Particular focus was paid to synthetic cathinones and participants were queried 
about use of 27 of these compounds including methylone ( “M1”), butylone ( “B1”), 
mephedrone (“MCAT”, “Meow Meow”), alpha-PVP (“Flakka”), and “bath salt unknown or not 
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listed”. Participants were also provided the opportunity to type in names of drugs they have 
ever used that were not queried in the survey.  
Those reporting lifetime use of ecstasy were asked “Have you ever tested your 
ecstasy/Molly using a drug testing kit?” and answer options were “yes” and “no”.  They were 
also asked “Did you ever find out that your ecstasy/Molly contained a drug other than MDMA?” 
and this question was not dependent on their response to the question about drug testing. 
Answer options were “yes”, “no”, and “unsure” and we dichotomised responses into “yes” vs. 
“no/unsure”. Those indicating past-year ecstasy use were also asked frequency of ecstasy pill 
use on an ordinal measure (Miech, Johnston, O’Malley, Bachman, & Schulenberg, 2016) which 
we recoded into 0-2 times, 3-19 times, and 20+ times.  
 
Hair analyses 
Among the 178 collected samples, 38 participants (21.3%) reported no lifetime ecstasy 
use, 20 (11.2%) reported lifetime use, but not past-year use, 90 (50.6%) reported past-year use, 
and 30 (16.9%) were unanalyzable due to inadequate quantity. These analyses focus on the 90 
participants with analysable hair samples who reported past-year ecstasy use.  
Since past-year use (particularly of NPS such as synthetic cathinones) was the primary 
outcome of interest, only the proximal 0-12 cm segment was analysed whenever a longer head 
hair sample was collected. Shorter head hair, as well as  arm, chest and leg hair samples were 
analysed in their full length. The average length was 8.4 ± 3.6 cm (median: 9.0 cm, IQR: 7.0). 
Assuming a normal hair growth rate (Kintz, 2013), the mean time frame is about 1 cm per 
month. A quantity of at least 20 mg was needed to perform the analysis. The specimens were 
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tested using two previously published methods using ultra-high performance liquid 
chromatography–tandem mass spectrometry (UHPLC-MS/MS). One (Di Corcia, D'Urso, Gerace, 
Salomone, & Vincenti, 2012) was used to screen for various common drugs including 
amphetamine, methamphetamine, MDA, MDMA, and MDEA. The other method (Salomone, 
Gazzilli, Di Corcia, Gerace, & Vincenti, 2016) screened for some of the most common NPS—
namely 12 synthetic cathinones (i.e., mephedrone [4-MMC], 4-MEC, methylone, 3,4-MDPV, 
pentedrone, 3-MMC, ethylcathinone, alpha-PVP, butylone, buphedrone, mexedrone, 
amfepramone), 6 other euphoric stimulants (i.e., 4-FA, 5/6-APB, 5-MAPB, mCPP, PMA, PMMA), 
3 dissociatives (i.e., MXE, 4-MeO-PCP, diphenidine), 6 psychedelic phenethylamines (i.e., 2C-B, 
2C-P, 25B-NBOMe, 25C-NBOMe, 25H-NBOMe, 25I-NBOMe), and 4 designer benzodiazepines 
(i.e., diclazepam, flubromazepam, nifoxipam, pyrazolam). This second method also tested for 
ketamine and PCP. We also tested for trazodone as mCPP is a metabolite of this substance so a 
positive test for trazodone in light of a positive test for mCPP would likely indicate trazodone 
use rather than use of mCPP (Lendoiro, Jiménez-Morigosa, Cruz, López-Rivadulla, & de Castro, 
2014).  
The limits of detection (LOD) of the analytical methods were set as the minimum 
criterion to identify the positive samples (Di Corcia et al., 2012; Salomone et al., 2016). LOD 
values ranged from 0.006 ng/mg for MDMA and 0.027 ng/mg for amphetamine for one method 
(Di Corcia et al., 2012), and from 0.9 pg/mg for 4-MeO-PCP up to 17 pg/mg for 6-APB, for the 





 We first examined the prevalence of self-reported drug use and positive test results. 
While prevalence of each separate compound was examined, we also examined prevalence of 
detecting positive for any synthetic cathinone, any NPS, and any discordant result which was 
defined as reporting no use of a specific drug but testing positive for that drug. We examined 
bivariable relations between these key outcomes and covariates using chi-square. Building 
upon bivariable statistics focusing on those who tested positive for synthetic cathinones, we 
examined conditional associations between each covariate and testing positive using multiple 
binary logistic regression. Further, we examined associations between each covariate with total 
number of positive tests for synthetic cathinones and total number of positive tests for NPS in 
general. We first examined potential differences in a bivariable manner using independent 
samples t-tests and then we examined all covariates simultaneously by fitting them into 
generalised negative binomial regression models which are robust to skewed discrete data. All 
statistical analyses were conducted using Stata SE 13 (StataCorp, College Station, TX, USA; 
2009). This study was approved by the authors’ institutional review board. 
 
Results 
Most participants identified as young adults (54.4%), female (53.3%), white (76.7%), and 
having earned a bachelor’s degree or higher (62.2%). The majority (55.6%) also reported 
attending an EDM party every other week or more often.  
Table 1 presents positive test results in comparison to self-reported past-year use. 
Three-quarters (74.4%) of the sample tested positive for MDMA. All participants testing positive 
for MDA or MDEA also tested positive for MDMA. Half of the samples tested positive for MDA 
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and 2 out of 10 (22.2%) of those testing positive specifically reported past-year use of MDA 
(commonly referred to as “sass” or “sassafras” in the US). About a third of the sample (32.2%) 
tested positive for methamphetamine and over a quarter (27.8%) of the sample tested positive 
for a synthetic cathinone. Butylone (14.4%), ethylone (11.1%), and pentylone (10.0%) were the 
most common synthetic cathinones detected; however, no participants reported past-year use 
of any of these specific compounds. Likewise, alpha-PVP was detected in 2.2% of the sample 
with no participants reporting use. However, despite 8.9% of the sample reporting lifetime use 
of methylone, only 3.3% tested positive for this compound. Similarly, while 2C-B use was 
reported by 11.1% of participants, only one participant tested positive for use.  
 Some participants tested positive for 4-FA (5.6%) or 5/6-APB (2.2%) and roughly half of 
these participants who tested positive also reported use (Table 1). With regard to dissociatives, 
more than half the sample (57.8%) tested positive for ketamine, and the majority (71.2%) of 
those testing positive also reported use. All participants who tested positive for another 
dissociative also tested positive for ketamine, and half of those testing positive for MXE use also 
reported use. It should be noted that five participants tested positive for mCPP; however, these 
cases also tested positive for trazodone, suggesting that mCPP was not in fact used (Lendoiro, 
et al., 2014). 
Table 2 presents sample characteristics according to whether the participant tested 
positive for MDMA, a synthetic cathinone, or any NPS, and whether the participant provided a 
discordant report meaning he or she tested positive for a drug despite reporting that the drug 
was never used. Those who tested positive for MDMA were more likely to report having used 
ecstasy pills in the last year more frequently, and all individuals reporting ecstasy pill use 20+ 
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times tested positive (p = 0.003). Results were somewhat similar for testing positive for 
synthetic cathinones or for any NPS. Specifically, those testing positive for synthetic cathinones 
(27.8%) or any NPS (33.3%) were more likely to report having attended an EDM parties more 
frequently (p = 0.015 and 0.016, respectively), more likely to report more frequent ecstasy pill 
use in the past 12 months (p = 0.005 and 0.015, respectively), and having tested their ecstasy (p 
= 0.016 and 0.006, respectively), and finding out their ecstasy was adulterated (p = 0.011 and 
0.047, respectively). Those testing positive for synthetic cathinones were also less likely to 
identify as white (p = 0.020). Regarding discordant findings, only those reporting having tested 
their ecstasy were at higher risk (p = 0.016).  
Since there were many significant differences regarding testing positive for synthetic 
cathinone use, we fit all covariates into a multivariable logistic regression model (Table 3). With 
all else being equal, white participants were at 80% lower odds of testing positive compared to 
those of other races, and higher frequency ecstasy pill use was associated with higher odds of 
testing positive. Significance of bivariable tests focusing on party attendance, drug testing, and 
finding out ecstasy has been adulterated was lost in the multivariable model. Despite having 
somewhat similar results in bivariable models, an identical model with testing positive for NPS 
in general as the outcome was non-significant (poor fit) with no significant covariates.  
 Finally, we examined the total number of synthetic cathinones (mean: 0.4 ± 0.8, median: 
0, range: 0-3) and overall NPS detected for each participant (mean: 2.1 ± 2.1, median: 1, range: 
0-9) (Table 4). Those reporting attending parties more frequently, those reporting using ecstasy 
pills 20+ times in the past 12 months, and those who reported having found out their ecstasy 
had been adulterated, tested positive for more synthetic cathinones and for more NPS in 
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general. White participants tested positive for fewer synthetic cathinones than non-white 
participants and females tested positive for fewer NPS in general than males. Those who 
reported ever testing their ecstasy also tested positive for more NPS than those who did not.  
 
Discussion 
Data on both known and unknown drug use in the EDM scene is important for informing 
prevention and harm reduction as this is a high-risk scene for drug use and adverse outcomes 
associated with drug use. In this study, we 1) examined prevalence of testing positive for 
specific drugs and drug classes, 2) determined the extent of discordant reporting, and 3) 
delineated characteristics of testing positive and/or providing a discordant report for select 
drug classes. As expected, while most past-year ecstasy users tested positive for MDMA, a large 
portion tested positive for drugs not reportedly used. 
Testing positive for drugs (particularly NPS such as synthetic cathinones) after not 
reporting use was common with half of participants (51.1%) having such a discordant result. 
Assuming participants provided truthful responses (Taylor, Sullivan, Ring, Macleod, & Hickman, 
2016), many unknowingly or unintentionally used drugs they did not report using. We 
hypothesise that many unreported drugs were likely present as adulterants in or replacements 
for drugs sold as ecstasy. Drugs such as PMMA and synthetic cathinones such as methylone and 
ethylone are frequently detected in drugs sold as ecstasy (Brunt et al., 2016; Brunt, Poortman, 
Niesink, & van den Brink, 2011; European Monitoring Centre for Drugs and Drug Addiction, 
2003; Hondebrink, Nugteren-van Lonkhuyzen, Van Der Gouwe, & Brunt, 2015; Vidal Gine et al., 
2016) or drugs that may have been sold as ecstasy (Caudevilla-Gálligo et al., 2013; Rust et al., 
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2012). Likewise, a recent study in Europe also detected 2C-B, 4-FA, and 5/6-APB in ecstasy 
(Brunt et al., 2016; Hondebrink et al., 2015). These drugs are likely chosen as adulterants, in 
part, as many of these compounds have somewhat similar effects as MDx. Although it is widely 
known that there can be adulterants in ecstasy, our combined use of surveys and biological 
testing suggests that a large number of participants are unaware of what they have consumed 
in the past.  
Unknown use of various drugs, however, could also have occurred resulting from use of 
other drugs sold as ketamine, methamphetamine, or LSD. For example, a drug testing study in 
Europe found 4-FA, 5/6-APB, MXE, and synthetic cathinones in cocaine and in 
amphetamine/methamphetamine (Hondebrink et al., 2015). The same study detected 
psychedelic phenethylamines such as 2C-B in LSD, and MXE and synthetic cathinones such as 
methylone in ketamine (Hondebrink et al., 2015). Energy Control in Spain recently reported that 
MXE was the most frequently discovered adulterant in ketamine (Energy Control, 2017) and 
likewise, we hypothesise that unknown use of NPS dissociatives was likely related to ketamine 
use as these drugs tend to have somewhat similar effects as ketamine (Winstock, Lawn, Deluca, 
& Borschmann, 2016).  
 Of note, there were participants who reported known use of synthetic cathinones such 
as methylone who tested positive for different synthetic cathinones such as butylone. It is 
unknown whether any of these participants actually used methylone or a different synthetic 




 Females tested positive for fewer NPS compared to males, and white participants tested 
positive for fewer synthetic cathinones than non-white participants. While females in the EDM 
scene are less likely to report NPS use (Palamar, Barratt, et al., 2016), we found that they also 
tend to test positive for fewer NPS. Our findings also corroborate our recent similar hair testing 
study that also found that white party attendees were less likely to test positive for synthetic 
cathinones such as butylone (Palamar, Salomone, et al., 2016). Educational attainment was not 
related to testing positive for NPS such as synthetic cathinones in this study; however, those 
reporting lower educational attainment were found to be at higher risk in the previous study 
(Palamar, Salomone, et al., 2016). Race/ethnicity and socioeconomic status (as is often 
indicated by educational attainment) tend to be closely intertwined in the US (Williams, Priest, 
& Anderson, 2016), so further research is needed to determine whether this race/ethnicity 
finding is in fact related to socioeconomic status or perhaps different social networks from 
where drugs are obtained.  
 Higher frequency of party attendance more than tripled the odds of testing positive for 
a synthetic cathinone, but this association only approached significance when controlling for all 
other covariates. A similar finding occurred regarding number of positive tests for synthetic 
cathinones, but more frequent attendance was remained a risk factor for testing positive for 
more NPS independent of all other covariates. These results add to and corroborate a previous 
hair study which found higher levels of party attendance are related to a higher risk of testing 
positive for synthetic cathinones (Palamar, Salomone, et al., 2016). These results also 
corroborate multiple previous studies that have found higher levels of party attendance are 
related to robust increases in risk of using a variety of drugs including synthetic cathinones and 
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other NPS (Palamar, Acosta, Ompad, et al., 2016; Palamar, Acosta, Sherman, et al., 2016; 
Palamar, Barratt, et al., 2016; Palamar et al., 2015).  
More frequent ecstasy users were not only more likely to test positive for synthetic 
cathinones and overall NPS, but they were also more likely to test positive for more compounds 
as frequency of use increased. Results were somewhat consistent when controlling for other 
covariates so results suggest that simply using ecstasy more frequently increases risk of using 
NPS. Testing ecstasy before use using reagent kits is a popular harm reduction method used to 
detect the presence of NPS such as synthetic cathinones. However, we found that reporting 
ever having tested one’s ecstasy was actually associated with testing positive for synthetic 
cathinones, overall NPS, and for a discordant finding (testing positive, but not reporting use). 
The association of testing, however, lost significance in all multivariable models. In addition, 
reporting having ever found out one’s ecstasy was adulterated was associated with testing 
positive for synthetic cathinones and overall NPS. This association disappeared regarding 
synthetic cathinone use in the multivariable model, but it remained a consistent risk factor for 
number of synthetic cathinones or NPS detected. More nuanced research is needed to 
determine whether drug testing (and results from such testing) is in fact an indicator of high 
risk for unknown or unintended consumption of NPS. Such tests help users detect adulterated 
samples as it is unknown, for example, whether some participants began testing their ecstasy 
after finding out they have used an adulterated product.  
Limitations  
 Hair samples were taken from a convenience sample as part of a larger epidemiology 
survey study. While this subsample is largely representative of the larger study, white 
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participants were at twice the odds for providing a hair sample than other races/ethnicities (P = 
0.002) which could have biased results. Our analyses were limited to self-reported past-12-
month ecstasy users; however, it is possible that unknown use of some drugs was not directly 
related to ecstasy use. While “known” use of each drug was queried on the survey, some 
participants may not have considered adulterants when answering. Self-reported drug use is 
also has limitations as drug use is a sensitive topic and individuals may not always provide 
honest responses. Importantly, it is possible that some individuals did not recall specific drugs 
they had used, did not know the names of drugs they have used, and/or they may had believed 
they were using a specific drug, but were in fact using a different drug. We did however present 
street names of drugs when possible and provided an option to type names of drugs into a text 
box if we did not query a specific drug they believe they had used.  In addition, we were not 
able to determine which instance(s) of drug use related to the specific compounds that tested 
positive, and hair was analysed in its full length in some cases which could bias results. Finally, 
some samples were not long enough to cover the past-year MDMA use, although they were still 
very informative about the past NPS use.   
Another limitation is that the questions asking about whether individuals had ever 
tested their ecstasy and had ever found out their ecstasy had been adulterated were not 
limited to the past-year timeframe. Despite this limitation, we believe these variables help 
determine whether individuals test their ecstasy (even if only once—regardless of recency) and 
whether individuals have experience learning their ecstasy has ever been adulterated 
(regardless of recency). In addition, while nearly 7 out of 10 cases testing positive for MDA did 
not report use, it should be noted that MDA frequently tests positive as a metabolite of MDMA 
19 
 
(Kintz, Cirimele, Tracqui, & Mangin, 1995; Liu, Liu, & Lin, 2006); therefore, despite increasing 
prevalence of MDA use (Palamar, Barratt, et al., 2016), MDA could have tested positive as a 
byproduct and may not have been directly ingested.  
 
Conclusions 
EDM parties are high-risk scenes due to both known and unknown drug use. Our results 
suggest drug-using EDM attendees in NYC are at risk for unintentionally or unknowingly using 
various psychoactive substances—particularly NPS such as synthetic cathinones. Although 
further research is needed to determine the drugs and instances in which these drugs were 
unknowingly used, our findings demonstrate that hair testing can serve as a valuable addition 
to epidemiology surveys in such high-risk scenes. There is still a strong need, however, for 
researchers to conduct studies on actual drug product (e.g., pills, powders) rather than 
biological specimens. Such results would not only provide better understanding of drug 
adulteration, but such studies would also be able to help determine whether providing users 
with results suggesting adulteration influence their decisions to continue use.  Research is also 
needed to determine whether providing users with results from biological tests (e.g., hair-
testing) suggesting adulteration affect future intentions to continue use. 
We have confirmed unknown consumption of a variety of drugs within this scene. 
Regardless of the source of adulteration, individuals in this scene need to be targeted with 
evidence-based information regarding the risks of using adulterated drugs. Harm reduction 
information and tactics can also likely help reduce harm when an individual decides to take the 
risk of using a potentially dangerous and often-adulterated drug such as ecstasy. Policy allowing 
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“drug-checking”—whether conducted by researchers, government officials, or harm reduction 
organisations—would likely help prevent harm among ecstasy users. However, more research is 
still needed to determine the extent to which harm reduction techniques such as “drug-
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Table 1  Prevalence of test results and self-reported use (N=90). 
 
Drug Name Drug Positive  
% (n) 
Self-Reported Past-
Year Use % (n) 
Discordant Positive 
(Lifetime Use) % (n) 
MDx    
   MDx (any)  74.4 (n=67) 100.0 (n=90) 0.0 (n=0) 
   MDMA 74.4 (n=67) 100.0 (n=90) 0.0 (n=0) 
   MDA 50.0 (n=45) 22.2 (n=20) 60.0 (n=27) 
   MDEA 15.6 (n=14) 0.0 (n=0) 100.0 (n=1) 
Common Stimulants     
   Amphetamine  41.1 (n=37) 40.0 (n=36) 37.8 (n=14) 
   Methamphetamine 32.2 (n=29) 13.3 (n=12) 55.2 (n=16) 
Synthetic Cathinones     
   Synthetic Cathinone (any) 27.8 (n=25) 12.2 (n=11) 68.0 (n=17) 
   Butylone  14.4 (n=13) 0.0 (n=0) 100.0 (n=13) 
   Ethylone  11.1 (n=10) 0.0 (n=0) 100.0 (n=10) 
   Pentylone  10.0 (n=9)  0.0 (n=0) 100.0 (n=9)  
   Methylone 3.3 (n=3) 8.9 (n=8)  33.3 (n=1) 
   Alpha-PVP 2.2 (n=2) 0.0 (n=0) 100.0 (n=2) 
Other Psychedelic Amphetamines    
   2C-B 1.1 (n=1) 11.1 (n=10) 100.0 (n=1) 
   PMMA 1.1 (n=1) 0.0 (n=0) 100.0 (n=1) 
Other Stimulants     
   4-FA 5.6 (n=5) 3.3 (n=3) 60.0 (n=3) 
   5/6-APB 2.2 (n=2)  2.2 (n=2) 50.0 (n=1) 
Dissociatives    
   Dissociative (any) 57.8 (n=52)  45.6 (n=41) 28.8 (n=15) 
   Ketamine  57.8 (n=52)  45.6 (n=41) 28.8 (n=15) 
   Methoxetamine 4.4 (n=4)  4.4 (n=4) 50.0 (n=2) 
   PCP 2.2 (n=2) 0.0 (n=0) 00.0 (n=0) 
   Diphenidine  1.1 (n=1) 0.0 (n=0) 100.0 (n=1) 
Note. The self-reported synthetic cathinone use categories included all synthetic cathinones assessed on the survey. 
Other than the five we tested for, there was one report of lifetime methedrone use, one report of lifetime 
methcathinone use, one report of lifetime mephedrone use, one report of past-year MPBP use, and one lifetime and 
one past-year report of use of an unknown “bath salt”. Participants were not asked specifically about PMMA or 
diphenidine use, but those who tested positive did not report use of these drugs (or similar drugs) via the type-in 
method. Only nonmedical use of amphetamine was assessed on the survey so it is possible some participants used in an 
approved medical manner. 
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Table 2  Prevalence of positive and discordant results for specific drug categories according to participant characteristics.  
 






Synthetic   





of Any Drug  
% 
Prevalence  -- 74.4 27.8 33.3 51.1 
Age      
   18-24 54.4 75.5 24.5 30.6 42.9 
   25-40 45.6 73.2 31.7 36.6 60.1 
Sex      
   Male 46.7 81.0 33.3 38.1 45.2 
   Female 53.3 68.8 22.9 29.1 56.3 
Race/Ethnicity      
   Non-White 23.3 81.0   47.6* 47.6 52.4 
   White 76.7 72.5 21.7 29.0 50.7 
Educational Attainment      
   Less than a Bachelor’s Degree 37.8 70.6 32.4 32.4 50.0 
   Bachelor’s Degree or Higher 62.2 76.8 25.0 33.9 51.8 
Nightclub Attendance      
   Less Than Once Every Other Week 44.4              70.0   15.0*   20.0* 42.5 
   Every Other Week or More Often 55.6 78.0 38.0 44.0 58.0 
Frequency of Past-Year Ecstasy Pill Use      
   0-2 Times 40.0     55.6**     11.1**   16.7* 38.9 
   3-19 Times 52.2 85.1 36.2 42.6 61.7 
   20+ Times    7.8              100.0 57.1 57.1 42.9 
Has Tested One’s Ecstasy          
   No 60.0 68.5   18.5*     22.2**  40.7* 
   Yes 40.0 83.3 41.7 50.0 66.7 
Ever Found Out Ecstasy Adulterated        
   No or Not Sure 61.1 69.1   18.2*   25.5* 45.5 
   Yes 38.9 82.9 42.9 45.7 60.0 
Note. “Discordant report” refers to when a participant’s hair tested positive for a drug that he or she did not report using. Comparisons were computed using 
chi-square analyses. NPS = new psychoactive substance.  
*p < 0.05, **p < 0.01
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Table 3  Bivariable and multivariable associations between covariates and testing positive for 
synthetic cathinones.  
 
 OR (95% CI) aOR (95% CI) 
Age     
   18-24 1.00  1.00  
   25-40 1.43 (0.57, 3.61) 2.35 (0.68, 8.16) 
Sex     
   Male 1.00  1.00  
   Female 0.59 (0.23, 1.51) 1.05 (0.68, 8.16) 
Race/Ethnicity     
   Non-White 1.00  1.00  
   White   0.31* (0.11, 0.86)   0.20* (0.05, 0.81) 
Educational Attainment     
   Less than a Bachelor’s Degree 1.00  1.00  
   Bachelor’s Degree or Higher 0.70 (0.27, 1.78) 1.07 (0.29, 3.96) 
Frequency of Party Attendance     
   Never through Monthly 1.00  1.00  
   Every Other Week or More   3.47* (1.23, 9.82) 3.08 (0.94, 10.08) 
Frequency of Past 12 Month Ecstasy Pill Use      
   0-2 Times 1.00  1.00  
   3-19 Times    4.40* (1.23, 15.72)    4.63* (1.00, 21.40) 
   20+ Times       6.15** (1.63, 23.19)    5.53* (1.06, 28.86) 
Has Tested One’s Ecstasy       
   No 1.00  1.00  
   Yes   3.14* (1.21, 8.16) 1.79 (0.55, 5.78) 
Ever Found Out Ecstasy was Adulterated     
   No or Not Sure  1.00  1.00  
   Yes   3.38* (1.29, 8.80) 2.92 (0.93, 9.19) 
Note. Estimates were computed using binary logistic regression. OR = odds ratio, aOR = adjusted odds 
ratio, CI = confidence interval.  




Table 4  Number of positive test results according to participant characteristics.   
 
 Sum of Samples Testing Positive  
for Synthetic Cathinones 
Sum of Samples Testing Positive  
for NPS 
 M (SD) aIRR (95% CI) M (SD) aIRR (95% CI) 
Age       
   18-24 0.3 (0.7) 1.00  2.2 (2.1) 1.00  
   25-40 0.5 (0.8) 1.25 (0.88, 3.80) 1.9 (2.2) 0.83 (0.57, 1.22) 
Sex       
   Male 0.5 (0.7) 1.00  2.7 (2.4) 1.00  
   Female 0.4 (0.8) 1.83 (0.58, 2.73)     1.5 (1.7)**     0.59** (0.40, 0.88) 
Race/Ethnicity       
   Non-White 0.9 (1.2) 1.00  2.3 (2.0) 1.00  
   White    0.3 (0.5)* 0.29** (0.13, 0.63) 2.0 (2.2) 1.10 (0.71, 1.70) 
Educational Attainment       
   Less than a Bachelor’s Degree 0.6 (1.0) 1.00  2.3 (2.0) 1.00  
   Bachelor’s Degree or Higher 0.3 (0.6) 1.06 (0.45, 2.48) 1.9 (2.2) 0.89 (0.60, 1.33) 
Nightclub Attendance       
   Less Than Once Every Other Week 0.2 (0.4) 1.00  1.4 (1.6) 1.00   
   Every Other Week or More Often      0.6 (0.9)** 2.47* (1.05, 5.83)     2.6 (2.4)**   1.56* (1.07, 1.27)  
Frequency of Past-Year Ecstasy Pill Use       
   0-2 Times 0.2 (0.5) 1.00  1.2 (1.3) 1.00  
   3-19 Times 0.6 (0.9) 2.57 (0.99, 6.71) 2.3 (2.1) 1.31 (0.82, 2.09) 
   20+ Times    0.7 (0.8)* 2.92* (1.03, 8.25)       4.9 (2.9)***   1.88* (1.16, 3.07) 
Has Tested One’s Ecstasy         
  No 0.3 (0.7) 1.00  1.5 (1.6) 1.00  
  Yes 0.6 (0.9) 1.39 (0.64, 3.01)     2.9 (2.5)** 1.34 (0.92, 1.95) 
Ever Found Out Ecstasy Adulterated         
   No or Not Sure 0.2 (0.4) 1.00  1.6 (1.8) 1.00  
   Yes      0.7 (1.0)** 2.45* (1.15, 5.24)   2.8 (2.4)*      1.67** (1.16, 2.40) 
Note. Bivariable comparisons of means were computed using independent samples t-tests. Generalised negative binomial regressions were used to compute 
multivariable statistics. M = mean, SD = standard deviation, aIRR = adjusted incidence rate ratio, CI = confidence interval, NPS = new psychoactive substance. *p 
<0 .05, **p < 0.01, ***p <0 .001  
 
